Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.

Puginier E, Bharatiya R, Chagraoui A, Manem J, Cho YH, Garret M, De Deurwaerdère P.

Neurochem Int. 2019 May 2;128:186-195. doi: 10.1016/j.neuint.2019.05.001. [Epub ahead of print]

PMID:
31054882
2.

Correlative analysis of dopaminergic and serotonergic metabolism across the brain to study monoaminergic function and interaction.

Dellu-Hagedorn F, Fitoussi A, De Deurwaerdère P.

J Neurosci Methods. 2017 Mar 15;280:54-63. doi: 10.1016/j.jneumeth.2017.01.020. Epub 2017 Feb 1.

PMID:
28161298
3.

Monoamines tissue content analysis reveals restricted and site-specific correlations in brain regions involved in cognition.

Fitoussi A, Dellu-Hagedorn F, De Deurwaerdère P.

Neuroscience. 2013;255:233-45. doi: 10.1016/j.neuroscience.2013.09.059. Epub 2013 Oct 10.

PMID:
24120557
4.

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease.

Callahan JW, Abercrombie ED.

Front Syst Neurosci. 2011 Jul 15;5:61. doi: 10.3389/fnsys.2011.00061. eCollection 2011.

5.

Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.

Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.

Neuroscience. 2009 Sep 29;163(1):456-65. doi: 10.1016/j.neuroscience.2009.06.014. Epub 2009 Jun 10.

PMID:
19524019
6.

Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.

Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P.

PLoS One. 2013 Sep 11;8(9):e75099. doi: 10.1371/journal.pone.0075099. eCollection 2013.

7.

Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice.

Lin Z, Dodd CA, Filipov NM.

Neurotoxicol Teratol. 2013 Sep-Oct;39:26-35. doi: 10.1016/j.ntt.2013.06.002. Epub 2013 Jun 14.

PMID:
23770127
8.

Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic changes.

Tucci P, Morgese MG, Colaianna M, Zotti M, Schiavone S, Cuomo V, Trabace L.

Steroids. 2012 Feb;77(3):269-75. doi: 10.1016/j.steroids.2011.12.014. Epub 2011 Dec 14.

PMID:
22197661
9.

Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat.

Sperk G, Berger M, Hörtnagl H, Hornykiewicz O.

Eur J Pharmacol. 1981 Sep 24;74(4):279-86.

PMID:
6170518
10.

Effects of chronic ethanol consumption and aging on dopamine, serotonin, and metabolites.

Woods JM, Druse MJ.

J Neurochem. 1996 May;66(5):2168-78.

PMID:
8780050
11.

Neurochemical effects of neuropeptide Y (NPY) and NPY2-36.

Drumheller A, Bouali SM, Fournier A, St-Pierre S, Jolicoeur FB.

Neuropeptides. 1994 Nov;27(5):291-6.

PMID:
7532289
12.

Effects of neonatal rat Borna disease virus (BDV) infection on the postnatal development of the brain monoaminergic systems.

Pletnikov MV, Rubin SA, Schwartz GJ, Carbone KM, Moran TH.

Brain Res Dev Brain Res. 2000 Feb 7;119(2):179-85.

PMID:
10675767
13.

Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.

Kreilaus F, Spiro AS, Hannan AJ, Garner B, Jenner AM.

J Huntingtons Dis. 2015;4(4):305-18. doi: 10.3233/JHD-150170.

PMID:
26639223
14.

Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients.

Storga D, Vrecko K, Birkmayer JG, Reibnegger G.

Neurosci Lett. 1996 Jan 12;203(1):29-32.

PMID:
8742039
15.

Relationship between subthalamic nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse model of Huntington's disease.

Callahan JW, Abercrombie ED.

J Physiol. 2015 Aug 15;593(16):3727-38. doi: 10.1113/JP270268. Epub 2015 Jun 25.

17.

Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice.

Mochel F, Durant B, Durr A, Schiffmann R.

PLoS One. 2011 Mar 31;6(3):e18336. doi: 10.1371/journal.pone.0018336.

18.

Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.

Kung VW, Hassam R, Morton AJ, Jones S.

Neuroscience. 2007 Jun 8;146(4):1571-80. Epub 2007 May 2.

PMID:
17478055
19.

Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.

Farrar AM, Callahan JW, Abercrombie ED.

Exp Neurol. 2011 Dec;232(2):119-25. doi: 10.1016/j.expneurol.2011.08.010. Epub 2011 Aug 16.

PMID:
21864528
20.

The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.

Hickey MA, Reynolds GP, Morton AJ.

J Neurochem. 2002 Apr;81(1):46-59.

Supplemental Content

Support Center